` DXR (Daxor Corp) vs S&P 500 Comparison - Alpha Spread

DXR
vs
S&P 500

Over the past 12 months, DXR has significantly outperformed S&P 500, delivering a return of +46% compared to the S&P 500's +12% growth.

Stocks Performance
DXR vs S&P 500

Loading
DXR
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
DXR vs S&P 500

Loading
DXR
S&P 500
Difference
www.alphaspread.com

Performance By Year
DXR vs S&P 500

Loading
DXR
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Daxor Corp vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Daxor Corp
Glance View

Market Cap
61.1m USD
Industry
Health Care

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. The company is headquartered in New York City, New York. The Company’s investment objectives are capital preservation, maintaining returns on capital with a high degree of safety and generating income from dividends and option sales to help offset operating losses from the Company’s operating division. The firm intends to maintain a diversified securities portfolio comprised primarily of electric utility company common and preferred stocks. The firm seeks to maintain a minimum of 80% of its portfolio in equity securities of utility companies.

DXR Intrinsic Value
3.3301 USD
Overvaluation 73%
Intrinsic Value
Price
Back to Top